Selective induction of cell-mediated immunity and protection of rhesus macaques from chronic SHIVKU2 infection by prophylactic vaccination with a conserved HIV-1 envelope peptide-cocktail

Virology

Volumn 370, Issue 1, 2008, Pages 130-141

  Nehete, Pramod N ^a   Nehete, Bharti P ^a   Hill, Lori ^a   Manuri, Pallavi R ^b   Baladandayuthapani, Veerabhadran ^b   Feng, Lei ^b   Simmons, Johnny ^a   Sastry, K Jagannadha ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cell mediated immunity; Dendritic cells; Peptide vaccine; Rhesus macaques; SHIV

Indexed keywords

DENDRITIC CELL VACCINE; FREUND ADJUVANT; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

AMINO ACID SEQUENCE; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS INFECTION; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VACCINATION; VIRUS STRAIN;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; CHRONIC DISEASE; CONSERVED SEQUENCE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MACACA MULATTA; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; VACCINATION; VACCINES, SYNTHETIC;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 36549059136     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.08.022     Document Type: Article

References (49)

1. Amara R.R.F., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., Montefiori D.C., Herndon G.S., Wyatt M.A., Candido N.L., Kozyr P.L., Earl J.M., Smith H.L.M., Grimm B.D., Hulsey M.L., Miller J., McClure H.M., McNicholl J.M., Moss B., and Robinson H.L. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 92 (2001) 69-74
2. Baba T.W., Liska V., Lehmann R.H., Vlasak J.W., Xu W., Ayehunie S., Cavacini L.A., Posner M.R., Katinger H., Stiegler G., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Lu Y., Wright J.E., Chou T., and Ruprecht R.M. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6 (2000) 200-206
3. Banchereau J., Paczesny S., Blanco P., Bennett L., Pascual V., Fay J., and Palucka A.K. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann. N. Y. Acad. Sci. 987 (2003) 180-187
4. Barouch D.H., and Letvin N.L. Viral evolution and challenges in the development of HIV vaccines. Vaccine 20 (2002) A66-A68
5. Barouch D.H., Fu T.M., Montefiori D.C., Lewis M.G., Shiver J.W., and Letvin N.L. Vaccine-elicited immune responses prevent clinical AIDS in SHIV (89.6P)-infected rhesus monkeys. Immunol. Lett. 79 (2001) 57-61
6. Barouch D.H., Kunstaman J., Juroda M.J., Schmitz J.E., Santra S., Peyerl F.W., Krivulka G.R., Beaudry K., Lifton M.A., Gotgone D.A., Montefiori D.C., Lewis M.G., Wolinsky S.M., and Letvin N.L. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415 (2002) 335-339
7. Barouch D.H., Kunstman J., Glowczwsi J., Kunstman K.J., Egan M.A., Peyerl F.W., Santra S., Kuroda M.J., Schmitz J.E., Beaudry K., Krivulka G.R., Lifton M.A., Gorgone D.A., Wolinkey S.M., and Letvin N.L. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J. Virol. 77 (2003) 7367-7375
8. Clerici M., Balotta C., Meroni L., Ferrario E., Riva C., Trabattoni D., Ridolfo A., Villa M., Shearer G.M., Moroni M., and Galli M. Type 1 cytokine production and low prevalence of viral isolation correlate with long-term nonprogression in HIV infection. AIDS Res. Hum. Retroviruses 12 (1996) 1053-1061
9. Fernando K., Hu H., Ni H., Hoxie J.A., and Weissman D. Vaccine-delivered HIV envelope inhibits CD4(+) T-cell activation, a mechanism for poor vaccine responses. Blood 109 (2007) 2538-2544
10. Gauduin M.C., Raymond P., Weir C., Barbas F., Burton D.R., and Koup R.A. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat. Med. 3 (1997) 1389-1393
11. Hel Z., Nacsa J., Kelsall B., Tsai W.P., Letvin N., Parks R.W., Tryniszewska E., Picker L., Lewis M.G., Edghill-Smith Y., Moniuszko M., Pal R., Stevceva L., Altman J.D., Allen T.M., Watkin D., Torres J.V., Berzofsky J.A., Belyako I.M., Strober W., and Franchini G. Impairment of Gag-specific CD8 (+) T-cell function in mucosal and systemic compartments of simian immunodeficiency virus mac251- and simian-human immunodeficiency virus KU2-infected macaques. J. Virol. 75 (2001) 11483-11495
12. Hel Z., Nacsa J., Tryniszewska E., Tsai W.P., Parks R.W., Montefiori D.C., Felber B.K., Tartaglia J., Pavlakis G.N., and Franchini G. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J. Immunol. 169 (2002) 4778-4787
13. HIV sequence Compendium, Leitner, T., Foley, B., Hahn, B., Marx, P., McCutchan, F., Mellora, J., Wolinsky, S., Kober, B. (Eds.) Theoretical Biology and Biophysics, Los Alamos, New Mexico, USA (2005).
14. Inaba K., Metlay J.P., Crowley M.T., and Steinman R.M. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J. Exp. Med. 172 (1990) 631-640
15. Joag S.V., Liu Z.Q., Stephens E.B., Smith M.S., Kumar A., Li Z., Wang C., Sheffer D., Jia F., Foresman L., Adany I., Lifson J., McClure H.M., and Narayan O. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS. J. Virol. 72 (1998) 9069-9078
16. Johnson R.P., Glickman R.L., Yang J.Q., Kaur A., Dion J.T., Mulligan M.J., and Desrosiers R.C. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J. Virol. 71 (1997) 7711-7718
17. Kawamura T., Gatanaga H., Borris D.L., Connors M., Mitsuya H., and Blauvelt A. Decreased stimulation of CD4+ T cell proliferation and IL-2 production by highly enriched populations of HIV-infected dendritic cells. J. Immunol. 170 (2003) 4260-4266
18. Kostense S., Koudstaal W., Sprangers M., Weverling G.J., Penders G., Helmus N., Vogels R., Bakker M., Berkhout B., Havenga M., and Goudsmit J. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18 (2004) 1213-1216
19. Kuroda M.J., Schmitz J.E., Charini W.A., Nickerson C.E., Lifton M.A., Lord C.I., Forman M.A., and Letvin N.L. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J. Immunol. 162 (1999) 5127-5133
20. Lekutis C., and Letvin N.L. HIV-1 envelope-specific CD4+ T helper cells from simian/human immunodeficiency virus-infected rhesus monkeys recognize epitopes restricted by MHC class II DRB1*0406 and DRB*W201 molecules. J. Immunol. 159 (1997) 2049-2057
21. Letvin N.L., Montefiori D.C., Yasutomi Y., Perry H.C., Davies M.H., Lekutis C., Alroy M., Freed D.C., Lord C.I., Handt L.K., Liu M.A., and J.Shiver W. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 9378-9383
22. Lu W., Wu X., Lu Y., Guo W., and Andrieu J.M. Therapeutic dendritic-cell vaccine for simian AIDS. Nat. Med. 9 (2003) 27-32
23. Masci A.M., Galgani M., Cassano S., Simone S.D., Gallo A., Rosa V.D., Zappacosta S., and Racioppi L. HIV-1 gp120 induces anergy in naive T lymphocytes through CD4-independent protein kinase-A-mediated signaling. J. Leukoc. Biol. 74 (2003) 1117-1124
24. Mascola J.R., Synder S.W., Weislow O.S., Belay S.M., Belshe R.B., Schwartz D.H., Clements M.L., Dolin R., Graham B.S., Gorse G.J., Keefer M.C., McElrah M.J., Walker M.C., Wagner K.F., McNeil J.G., McCutchan F.E., and Burke D.S. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J. Infect. Dis. 173 (1996) 340-348
25. Mascola J.R., Lewis M.G., VanCott T.C., Stiegler G., Katinger H., Seaman M., Beaudry K., Barouch D.H., Korioth-Schmitz B., Kivulka G., Sambor A., Welcher B., Douek D.C., Montefiori D.C., Shiver J.W., Poignard P., Burton D.R., and Letvin N.L. Defining the protective antibody response for HIV-1 Cellular immunity elicited by human immunodeficiency virus type 1/simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. Curr. Mol. Med. 3 (2003) 209-216
26. McMichael A.J., and Rowland-Jones S.L. Cellular immune responses to HIV. Nature 410 (2001) 980-987
27. Migueles S.A., Laborico A.C., Shupert W.L., Sabbaghian M.S., Rabin R., Hallahan C.W., Van Baarle D., Kostense S., Miedema F., McLaughlin M., Ehler L., Metcalf J., Liu S., and Connors M. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3 (2002) 1061-1068
28. Nehete P.N., Satterfield W.C., Matherne C.M., Arlinghaus R.B., and Sastry K.J. Induction of human immunodeficiency virus-specific T cell responses in rhesus monkeys by synthetic peptides from gp160. AIDS Res. Hum. Retroviruses 9 (1993) 235-240
29. Nehete P.N., Johnson P.C., Murthy K.K., Schpiro S.J., and Sastry K.J. A synthetic peptide from the first conserved region in the envelope protein gp160 is a strong T-cell epitope in HIV-infected chimpanzees and humans. Viral Immunol. 11 (1998) 147-158
30. Nehete P.N., Lewis D.E., Tang D.N., Pollack M.S., and Sastry K.J. Presence of HLA-C-restricted cytotoxic T-lymphocyte responses in long-term nonprogressors infected with human immunodeficiency virus. Viral Immunol. 11 (1998) 119-129
31. Nehete P.N., Chitta S., Hossain M.M., Hill L., Bernaky B.J., Baze W., Arlighaus R.B., and Sastry K.J. Protection against chronic infection and AIDS by HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model. Vaccine 20 (2002) 813-825
32. Nehete P.N., Gambhira R., Nehete B.P., and Sastry K.J. Dendritic cells enhance detection of antigen-specific cellular immune responses by lymphocytes from rhesus macaques immunized with an HIV envelope peptide cocktail vaccine. J. Med. Primatol. 32 (2003) 67-73
33. Nehete P.N., Nehete B.N., Manuri P., Hill L., Palmer J.L., and Sastry K.J. Protection by dendritic cells-based HIV synthetic peptide cocktail vaccine: Preclinical studies in the SHIV-rhesus model. Vaccine 23 (2005) 2154-2159
34. Nilsson C., Makitalo B., Thorstensson R., Norley S., Binninger-Schinzel D., Cranage M., Rud E., Biberfeld G., and Putkonen P. Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. AIDS 12 (1998) 2261-2270
35. O'Doherty U., Ignatius R., Bhardwaj N., and Pope M. Generation of monocytederived dendritic cells from precursors in rhesus macaque blood. J. Immunol. Methods 207 (1997) 185-194
36. Poignard P., Sabbe R., Picchio G.R., Wang M., Gulizia R.J., Katinger H., Parren P., Mosier D.E., and Burton D.R. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 10 (1999) 431-438
37. Pope M. Dendritic cells as a conduit to improve HIV vaccines. Curr. Mol. Med. 3 (2003) 229-242
38. Rinaldo C., Huang X.L., Fan Z.F., Ding M., Beltz L., Logar A., Panicali D., Mazzara G., Liebmann J., and Cottrill M. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term nonprogressors. J. Virol. 69 (1995) 5838-5842
39. Robbins J.B., Schneerson R., and Szu S.C. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171 (1995) 1387-1398
40. Robinson H.L., Montefiori D.C., Johnson R.P., Manson K.H., Kalish M.L., Lifson J.D., Rizvi T.A., Lu S., Hu S.L., Mazzara G.P., Panicali D.L., Herndon J.G., Glickman R., Candido M.A., Lydy S.L., Wyand M.S., and McClure H.M. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat. Med. 5 (1999) 26-34
41. Rowland-Jones S.L., and Douglas N. HIV-specific CTL activity in an HIV-exposed but uninfected infant. Lancet 341 (1993) 860-861
42. Rowland-Jones S.L., Sutton J., Ariyoshi K., Dong T., Gotch F., McAdam S., Whitby D., Sabally S., Gallimore A., Corrah T., Takiguchi M., Schultz T., McMichael A., and Whittle H. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1 (1995) 59-64
43. Sastry K.J., and Arlinghaus R.B. Identification of T-cell epitopes without B-cell activity in the first and second conserved regions of the HIV Env protein. AIDS 5 (1991) 699-707
44. Shearer G.M., and Clerici M. Cytokine profiles in HIV type 1 disease and protection. AIDS Res. Hum. Retroviruses 14 Suppl. 2 (1998) S149-S152
45. Singh D.K., Liu Z., Sheffer D., Mackay G.A., Smith M., Dhillon S., Hegde R., Jia F., Adany I., and Narayan O. A noninfectious simian/human immunodeficiency virus DNA vaccine that protects macaques against AIDS. J. Virol. 79 (2005) 3419-3428
46. Srivastava I.K., Ulmer J.B., and Barnett S.W. Role of neutralizing antibodies in protective immunity against HIV. Human Vaccines 1 (2005) 45-60
47. Steinman R.M., Granelli-Piperno A., Pope M., Trumpftheller C., Ignatius R., Arrode G., Racz P., and Tenner-Racz K. The interaction of immunodeficiency viruses with dendritic cells. Curr. Top Microbiol. Immunol. 276 (2003) 1-30
48. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H., Bender A., Maczek C., Schreiner D., von den Driesch P., Brocker E.B., Steiman R.M., Enk A., Kampgen E., and Schuler G. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190 (1999) 1669-1678
49. Wahren B., Rosen J., Sandstrom E., Mathiesen T., Modrow S., and Wigzell H. HIV-1 peptides induce a proliferative response in lymphocytes from infected persons. J. Acquired Immune Defic. Syndr. 2 (1989) 448-456